 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of acute liver [0m
[34minjury?[0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CLONAZEPAM increase or decrease the risk of acute liver [0m
[32minjury?[0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"CLONAZEPAM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CLONAZEPAM: precautions: Data for other benzodiazepines suggest the possibility of adverse developmental effects [0m[1;31m([0m[31mlong-term effects on neurobehavioral and immunological function[0m[1;31m)[0m[31m in animals [0m
[31mfollowing prenatal exposure to benzodiazepines. Nursing Mothers: Risk Summary Clonazepam is excreted in human milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed [0m
[31mto benzodiazepines through breast milk. There are no data on the effects of clonazepam on milk production. The developmental and health benefits of breastfeeding should be considered along with the [0m
[31mmother's clinical need for clonazepam tablets and any potential adverse effects on the breastfed infant from clonazepam tablets or from the underlying maternal condition. Clinical Considerations [0m
[31mInfants exposed to clonazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain. CLONAZEPAM: precautions: Pediatric Use: Because of the possibility that adverse [0m
[31meffects on physical or mental development could become apparent only after many years, a benefit-risk consideration of the long-term use of clonazepam tablets is important in pediatric patients being [0m
[31mtreated for seizure disorder [0m[1;31m([0m[31msee INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Safety and effectiveness in pediatric patients with panic disorder below the age of [0m[1;31m18[0m[31m have not been [0m
[31mestablished. Geriatric Use: Clinical studies of clonazepam tablets did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. [0m
[31mOther reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually [0m
[31mstarting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. CLONAZEPAM: [0m
[31mprecautions: Because clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair clonazepam elimination. Metabolites of clonazepam tablets are excreted by the kidneys; to [0m
[31mavoid their excess accumulation, caution should be exercised in the administration of the drug to patients with impaired renal function. Because elderly patients are more likely to have decreased [0m
[31mhepatic and/or renal function, care should be taken in dose selection, and it may be useful to assess hepatic and/or renal function at the time of dose selection. Sedating drugs may cause confusion [0m
[31mand over-sedation in the elderly; elderly patients generally should be started on low doses of clonazepam tablets and observed closely.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: adverse_reactions: â€  Indicates that the p-value for the dose-trend test [0m[1;31m([0m[31mCochran-Mantel-Haenszel[0m[1;31m)[0m[31m for adverse event incidence was â‰¤ [0m[1;31m0.10[0m[31m. â€¡ Denominators for events in [0m
[31mgender-specific systems are: n = [0m[1;31m240[0m[31m [0m[1;31m([0m[31mclonazepam[0m[1;31m)[0m[31m, [0m[1;31m102[0m[31m [0m[1;31m([0m[31mplacebo[0m[1;31m)[0m[31m for male, and [0m[1;31m334[0m[31m [0m[1;31m([0m[31mclonazepam[0m[1;31m)[0m[31m, [0m[1;31m192[0m[31m [0m[1;31m([0m[31mplacebo[0m[1;31m)[0m[31m for female. CLONAZEPAM: adverse_reactions: Clonazepam Maximum Daily Dose Adverse Event by[0m
[31mBody System < [0m[1;31m1[0m[31m mg n = [0m[1;31m96[0m[31m % [0m[1;31m1[0m[31m - < [0m[1;31m2[0m[31m mg n = [0m[1;31m129[0m[31m % [0m[1;31m2[0m[31m - < [0m[1;31m3[0m[31m mg n = [0m[1;31m113[0m[31m % â‰¥ [0m[1;31m3[0m[31m mg n = [0m[1;31m235[0m[31m % All Clonazepam Tablets Groups N = [0m[1;31m574[0m[31m % Placebo N = [0m[1;31m294[0m[31m % Central & Peripheral Nervous System Somnolence â€  [0m[1;31m26[0m[31m [0m[1;31m35[0m[31m [0m
[1;31m50[0m[31m [0m[1;31m36[0m[31m [0m[1;31m37[0m[31m [0m[1;31m10[0m[31m Dizziness [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m Coordination Abnormal â€  [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m7[0m[31m [0m[1;31m9[0m[31m [0m[1;31m6[0m[31m [0m[1;31m0[0m[31m Ataxia â€  [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m5[0m[31m [0m[1;31m0[0m[31m Dysarthria â€  [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Psychiatric Depression [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m7[0m[31m [0m[1;31m1[0m[31m Memory Disturbance [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m Nervous [0m
[31mCLONAZEPAM: adverse_reactions: ness [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Intellectual Ability Reduced [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Emotional Lability [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Libido Decreased [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Confusion [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Respiratory System Upper [0m
[31mRespiratory Tract Infection â€  [0m[1;31m10[0m[31m [0m[1;31m10[0m[31m [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m Sinusitis [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Rhinitis [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Coughing [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Pharyngitis [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Bronchitis [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Gastrointestinal System Constipation â€  [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m5[0m[31m [0m
[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Appetite Decreased [0m[1;31m1[0m[31m CLONAZEPAM: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Abdominal Pain â€  [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Body as a Whole Fatigue [0m[1;31m9[0m[31m [0m[1;31m6[0m[31m [0m[1;31m7[0m[31m [0m[1;31m7[0m[31m [0m[1;31m7[0m[31m [0m[1;31m4[0m[31m Allergic Reaction [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Musculoskeletal Myalgia [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m
[31mResistance Mechanism Disorders Influenza [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Urinary System Micturition Frequency [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Urinary Tract Infection â€  [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Vision Disorders Blurred Vision [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Reproductive [0m
[31mDisorders â€¡ Female Dysmenorrhea [0m[1;31m0[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Colpitis [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Male Ejaculation Delayed CLONAZEPAM: adverse_reactions: [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Impotence [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Commonly Observed Adverse Events: Table [0m[1;31m4[0m[31m. [0m
[31mIncidence of Most Commonly Observed Adverse Events * in Acute Therapy in Pool of [0m[1;31m6[0m[31m- to [0m[1;31m9[0m[31m-Week Trials * Treatment-emergent events for which the incidence in the clonazepam patients was â‰¥ [0m[1;31m5[0m[31m% and at [0m
[31mleast twice that in the placebo patients.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: geriatric_use: Geriatric Use: Clinical studies of clonazepam tablets did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently [0m
[31mfrom younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should[0m
[31mbe cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. [0m
[31mBecause clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair clonazepam elimination. Metabolites of clonazepam tablets are excreted by the kidneys; to avoid their [0m
[31mexcess accumulation, caution should be exercised in the administration of the drug to patients with impaired renal function. CLONAZEPAM: geriatric_use: Because elderly patients are more likely to have[0m
[31mdecreased hepatic and/or renal function, care should be taken in dose selection, and it may be useful to assess hepatic and/or renal function at the time of dose selection. Sedating drugs may cause [0m
[31mconfusion and over-sedation in the elderly; elderly patients generally should be started on low doses of clonazepam tablets and observed closely.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: contraindications: CONTRAINDICATIONS Clonazepam tablets are contraindicated in patients with the following conditions: History of sensitivity to benzodiazepines Clinical or [0m
[31mbiochemical evidence of significant liver disease Acute narrow angle glaucoma [0m[1;31m([0m[31mit may be used in patients with open angle glaucoma who are receiving appropriate therapy[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: spl_medguide: Like other antiepileptic medicines, clonazepam tablets may cause suicidal thoughts or actions in a very small number of people, about [0m[1;31m1[0m[31m in [0m[1;31m500[0m[31m. Call your healthcare [0m
[31mprovider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse [0m
[31manxiety feeling agitated or restless panic attacks trouble sleeping [0m[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m acting on dangerous impulses new or worse irritability an extreme increase in activity and talking [0m[1;31m([0m[31mmania[0m[1;31m)[0m[31m acting [0m
[31maggressive, being angry, or violent other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden [0m
[31mchanges, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are [0m
[31mworried about symptoms. CLONAZEPAM: spl_medguide: Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may [0m
[31mcheck for other causes. Do not stop clonazepam tablets without first talking to a healthcare provider. Stopping clonazepam tablets suddenly can cause serious problems. Stopping clonazepam tablets [0m
[31msuddenly can cause seizures that will not stop [0m[1;31m([0m[31mstatus epilepticus[0m[1;31m)[0m[31m. What are clonazepam tablets? Clonazepam tablets are a prescription medicine used alone or with other medicines to treat: certain [0m
[31mtypes of seizure disorders [0m[1;31m([0m[31mepilepsy[0m[1;31m)[0m[31m in adults and children panic disorder with or without fear of open spaces [0m[1;31m([0m[31magoraphobia[0m[1;31m)[0m[31m in adults Clonazepam tablets are a federally controlled substance [0m[1;31m([0m[31mC-IV[0m[1;31m)[0m[31m [0m
[31mbecause it contains clonazepam that can be abused or lead to dependence. Keep clonazepam tablets in a safe place to prevent misuse and abuse. CLONAZEPAM: spl_medguide: Selling or giving away [0m
[31mclonazepam tablets may harm others, and is against the law. Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs. It is not known[0m
[31mif clonazepam tablets are safe or effective in treating panic disorder in children younger than [0m[1;31m18[0m[31m years old. Who should not take clonazepam tablets? Do not take clonazepam tablets if you: are [0m
[31mallergic to benzodiazepines have significant liver disease have an eye disease called acute narrow angle glaucoma Ask your healthcare provider if you are not sure if you have any of the problems [0m
[31mlisted above. Before you take clonazepam tablets, tell your healthcare provider if you: have liver or kidney problems have lung problems [0m[1;31m([0m[31mrespiratory disease[0m[1;31m)[0m[31m have or have had depression, mood [0m
[31mproblems, or suicidal thoughts or behavior have any other medical problems are pregnant or plan to become pregnant. CLONAZEPAM: spl_medguide: Taking clonazepam tablets late in pregnancy may cause your[0m
[31mbaby to have symptoms of sedation [0m[1;31m([0m[31mbreathing problems, sluggishness, low muscle tone[0m[1;31m)[0m[31m, and/or withdrawal symptoms [0m[1;31m([0m[31mjitteriness, irritability, restlessness, shaking, excessive crying, feeding [0m
[31mproblems[0m[1;31m)[0m[31m. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with clonazepam tablets. If you become pregnant while taking clonazepam tablets, [0m
[31mtalk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can register by calling [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m. The purpose of this registry is to collect[0m
[31minformation about the safety of antiepileptic drugs during pregnancy. are breastfeeding or plan to breastfeed. Clonazepam can pass into breast milk. Breastfeeding during treatment with clonazepam [0m
[31mtablets may cause your baby to have sleepiness, feeding problems, and decreased weight gain. CLONAZEPAM: spl_medguide: Talk to your healthcare provider about the best way to feed your baby while you [0m
[31mtake clonazepam tablets. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking clonazepam [0m
[31mtablets with certain other medicines can cause side effects or affect how well clonazepam tablets or the other medicines work. Do not start or stop other medicines without talking to your healthcare [0m
[31mprovider. How should I take clonazepam tablets? Take clonazepam tablets exactly as your healthcare provider tells you. If you take clonazepam tablets for seizures, your healthcare provider may change [0m
[31mthe dose until you are taking the right amount of medicine to control your symptoms. Clonazepam is available as a tablet. Do not stop taking clonazepam tablets without first talking to your healthcare[0m
[31mprovider. Stopping clonazepam tablets suddenly can cause serious problems. Clonazepam tablets should be taken with water and swallowed whole.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. The use of benzodiazepines, [0m
[31mincluding clonazepam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other[0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. CLONAZEPAM: boxed_warning: Before prescribing clonazepam tablets and [0m
[31mthroughout treatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m . The continued use of benzodiazepines, including clonazepam tablets, may lead to clinically [0m
[31msignificant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of clonazepam [0m
[31mtablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clonazepam tablets[0m
[31mor reduce the dosage [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m .         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: adverse_reactions: While these findings are noteworthy, Hamilton Depression Rating Scale [0m[1;31m([0m[31mHAM-D[0m[1;31m)[0m[31m data collected in these trials revealed a larger decline in HAM-D scores in the [0m
[31mclonazepam group than the placebo group suggesting that clonazepam-treated patients were not experiencing a worsening or emergence of clinical depression. Other Adverse Events Observed During the [0m
[31mPremarketing Evaluation of Clonazepam Tablets in Panic Disorder: Following is a list of modified CIGY terms that reflect treatment-emergent adverse events reported by patients treated with clonazepam [0m
[31mtablets at multiple doses during clinical trials. All reported events are included except those already listed in Table [0m[1;31m3[0m[31m or elsewhere in labeling, those events for which a drug cause was remote, [0m
[31mthose event terms which were so general as to be uninformative, and events reported only once and which did not have a substantial probability of being acutely life-threatening. CLONAZEPAM: [0m
[31madverse_reactions: It is important to emphasize that, although the events occurred during treatment with clonazepam tablets, they were not necessarily caused by it. Events are further categorized by [0m
[31mbody system and listed in order of decreasing frequency. These adverse events were reported infrequently, which is defined as occurring in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients. CLONAZEPAM: adverse_reactions: Body[0m
[31mas a Whole: weight increase, accident, weight decrease, wound, edema, fever, shivering, abrasions, ankle edema, edema foot, edema periorbital, injury, malaise, pain, cellulitis, inflammation localized[0m
[31mCardiovascular Disorders: chest pain, hypotension postural Central and Peripheral Nervous System Disorders: migraine, paresthesia, drunkenness, feeling of enuresis, paresis, tremor, burning skin, [0m
[31mfalling, head fullness, hoarseness, hyperactivity, hypoesthesia, tongue thick, twitching Gastrointestinal System Disorders: abdominal discomfort, gastrointestinal inflammation, stomach upset, [0m
[31mtoothache, flatulence, pyrosis, saliva increased, tooth disorder, bowel movements frequent, pain pelvic, dyspepsia, hemorrhoids Hearing and Vestibular Disorders: vertigo, otitis, earache, motion [0m
[31msickness Heart Rate and Rhythm Disorders: palpitation Metabolic and Nutritional Disorders: thirst CLONAZEPAM: adverse_reactions: , gout Musculoskeletal System Disorders: back pain, fracture traumatic,[0m
[31msprains and strains, pain leg, pain nape, cramps muscle, cramps leg, pain ankle, pain shoulder, tendinitis, arthralgia, hypertonia, lumbago, pain feet, pain jaw, pain knee, swelling knee Platelet, [0m
[31mBleeding and Clotting Disorders: bleeding dermal Psychiatric Disorders: insomnia, organic disinhibition, anxiety, depersonalization, dreaming excessive, libido loss, appetite increased, libido [0m
[31mincreased, reactions decreased, aggression, apathy, disturbance in attention, excitement, anger, hunger abnormal, illusion, nightmares, sleep disorder, suicide ideation, yawning Reproductive [0m
[31mDisorders, Female: breast pain, menstrual irregularity Reproductive Disorders, Male: ejaculation decreased Resistance Mechanism Disorders: infection mycotic, infection viral, infection streptococcal, [0m
[31mherpes simplex infection, infectious mononucleosis, moniliasis Respir CLONAZEPAM: adverse_reactions: atory System Disorders: sneezing excessive, asthmatic attack, dyspnea, nosebleed, pneumonia, [0m
[31mpleurisy Skin and Appendages Disorders: acne flare, alopecia, xeroderma, dermatitis contact, flushing, pruritus, pustular reaction, skin burns, skin disorder Special Senses Other, Disorders: taste [0m
[31mloss Urinary System Disorders: dysuria, cystitis, polyuria, urinary incontinence, bladder dysfunction, urinary retention, urinary tract bleeding, urine discoloration Vascular [0m[1;31m([0m[31mExtracardiac[0m[1;31m)[0m[31m Disorders:[0m
[31mthrombophlebitis leg Vision Disorders: eye irritation, visual disturbance, diplopia, eye twitching, styes, visual field defect, xerophthalmia         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: clinical_pharmacology: CLINICAL PHARMACOLOGY Pharmacodynamics: The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is [0m
[31mbelieved to be related to its ability to enhance the activity of gamma aminobutyric acid [0m[1;31m([0m[31mGABA[0m[1;31m)[0m[31m, the major inhibitory neurotransmitter in the central nervous system. Pharmacokinetics: Clonazepam is [0m
[31mrapidly and completely absorbed after oral administration. The absolute bioavailability of clonazepam is about [0m[1;31m90[0m[31m%. Maximum plasma concentrations of clonazepam are reached within [0m[1;31m1[0m[31m to [0m[1;31m4[0m[31m hours after [0m
[31moral administration. Clonazepam is approximately [0m[1;31m85[0m[31m% bound to plasma proteins. Clonazepam is highly metabolized, with less than [0m[1;31m2[0m[31m% unchanged clonazepam being excreted in the urine. Biotransformation [0m
[31moccurs mainly by reduction of the [0m[1;31m7[0m[31m-nitro group to the [0m[1;31m4[0m[31m-amino derivative. CLONAZEPAM: clinical_pharmacology: This derivative can be acetylated, hydroxylated and glucuronidated. Cytochrome P-[0m[1;31m450[0m[31m [0m
[31mincluding CYP3A, may play an important role in clonazepam reduction and oxidation. The elimination half-life of clonazepam is typically [0m[1;31m30[0m[31m to [0m[1;31m40[0m[31m hours. Clonazepam pharmacokinetics are dose-independent[0m
[31mthroughout the dosing range. There is no evidence that clonazepam induces its own metabolism or that of other drugs in humans. Pharmacokinetics in Demographic Subpopulations and in Disease States: [0m
[31mControlled studies examining the influence of gender and age on clonazepam pharmacokinetics have not been conducted, nor have the effects of renal or liver disease on clonazepam pharmacokinetics been [0m
[31mstudied. Because clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair clonazepam elimination. CLONAZEPAM: clinical_pharmacology: Thus, caution should be exercised [0m
[31mwhen administering clonazepam to these patients [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. In children, clearance values of [0m[1;31m0.42[0m[31m Â± [0m[1;31m0.32[0m[31m mL/min/kg [0m[1;31m([0m[31mages [0m[1;31m2[0m[31m to [0m[1;31m18[0m[31m years[0m[1;31m)[0m[31m and [0m[1;31m0.88[0m[31m Â± [0m[1;31m0.4[0m[31m mL/min/kg [0m[1;31m([0m[31mages [0m[1;31m7[0m[31m to [0m[1;31m12[0m[31m years[0m[1;31m)[0m[31m were[0m
[31mreported; these values decreased with increasing body weight. Ketogenic diet in children does not affect clonazepam concentrations. Clinical Trials: Panic Disorder: The effectiveness of clonazepam [0m
[31mtablets in the treatment of panic disorder was demonstrated in two double-blind, placebo-controlled studies of adult outpatients who had a primary diagnosis of panic disorder [0m[1;31m([0m[31mDSM-IIIR[0m[1;31m)[0m[31m with or [0m
[31mwithout agoraphobia. CLONAZEPAM: clinical_pharmacology: In these studies, clonazepam tablets were shown to be significantly more effective than placebo in treating panic disorder on change from [0m
[31mbaseline in panic attack frequency, the Clinicianâ€™s Global Impression Severity of Illness Score and the Clinicianâ€™s Global Impression Improvement Score. Study [0m[1;31m1[0m[31m was a [0m[1;31m9[0m[31m-week, fixed-dose study [0m
[31minvolving clonazepam tablets doses of [0m[1;31m0.5[0m[31m, [0m[1;31m1[0m[31m, [0m[1;31m2[0m[31m, [0m[1;31m3[0m[31m or [0m[1;31m4[0m[31m mg/day or placebo. This study was conducted in four phases: a [0m[1;31m1[0m[31m-week placebo lead-in, a [0m[1;31m3[0m[31m-week upward titration, a [0m[1;31m6[0m[31m-week fixed dose, and a [0m
[1;31m7[0m[31m-week discontinuance phase. A significant difference from placebo was observed consistently only for the [0m[1;31m1[0m[31m mg/day group. The difference between the [0m[1;31m1[0m[31m mg dose group and placebo in reduction from [0m
[31mbaseline in the number of full panic attacks was approximately [0m[1;31m1[0m[31m panic attack per week.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Clonazepam is contraindicated in patients with clinical or biochemical evidence of significant liver disease, which implies that it may increase the risk of liver injury or be harmful in the [0m
[32mpresence of liver disease. The label specifically states that because clonazepam undergoes hepatic metabolism, liver disease could impair clonazepam elimination. Therefore, caution is advised when [0m
[32madministering clonazepam to patients with liver disease, and it may be useful to assess hepatic function at the time of dose selection.[0m

[32mSOURCE: CLONAZEPAM label[0m
[32mEXTRACT_START_END: CONTRAINDICATIONS Clonazepam tablets are contraindicated[0m[32m...[0m[32msignificant liver disease[0m[32m...[0m
*[1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Clonazepam is contraindicated in patients with clinical or [0m
[34mbiochemical evidence of significant liver disease, which implies that it may increase the risk of liver injury or be harmful in the presence of liver disease. The label specifically states that [0m
[34mbecause clonazepam undergoes hepatic metabolism, liver disease could impair clonazepam elimination. Therefore, caution is advised when administering clonazepam to patients with liver disease, and it [0m
[34mmay be useful to assess hepatic function at the time of dose selection.[0m

[34mSOURCE: CLONAZEPAM label[0m
[34mEXTRACT_START_END: CONTRAINDICATIONS Clonazepam tablets are contraindicated[0m[34m...[0m[34msignificant liver disease[0m[34m...[0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that CLONAZEPAM is contraindicated in patients with clinical or biochemical evidence of significant liver disease, which suggests that it may increase the risk of liver [0m
[32minjury or be harmful in the presence of liver disease. The label indicates that because clonazepam undergoes hepatic metabolism, liver disease could impair clonazepam elimination. Therefore, caution [0m
[32mis advised when administering clonazepam to patients with liver disease."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"CLONAZEPAM may increase the risk of liver injury, especially in patients with pre-existing liver disease. It is contraindicated in patients with significant liver disease, and caution [0m
[32mis advised when administering it to patients with liver disease due to potential impairment of drug elimination."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CLONAZEPAM increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that CLONAZEPAM is contraindicated in patients with clinical or biochemical evidence of significant liver disease, which suggests that it may increase the risk of liver [0m
[34minjury or be harmful in the presence of liver disease. The label indicates that because clonazepam undergoes hepatic metabolism, liver disease could impair clonazepam elimination. Therefore, caution [0m
[34mis advised when administering clonazepam to patients with liver disease."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"CLONAZEPAM may increase the risk of liver injury, especially in patients with pre-existing liver disease. It is contraindicated in patients with significant liver disease, and caution [0m
[34mis advised when administering it to patients with liver disease due to potential impairment of drug elimination."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CLONAZEPAM increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that CLONAZEPAM is contraindicated in patients with clinical or biochemical evidence of significant liver disease, which suggests that it may increase the risk of liver injury [0m
[31mor be harmful in the presence of liver disease. The label indicates that because clonazepam undergoes hepatic metabolism, liver disease could impair clonazepam elimination. Therefore, caution is [0m
[31madvised when administering clonazepam to patients with liver disease.[0m
[31m        -----[0m
[31m        Final answer: CLONAZEPAM may increase the risk of liver injury, especially in patients with pre-existing liver disease. It is contraindicated in patients with significant liver disease, and [0m
[31mcaution is advised when administering it to patients with liver disease due to potential impairment of drug elimination.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent with medical knowledge and common sense. The contraindication in patients with significant liver disease and the caution advised for patients with[0m
[32mliver disease due to potential impairment of drug elimination logically support the conclusion that clonazepam may increase the risk of liver injury, especially in those with pre-existing liver [0m
[32mconditions. No specific flaws are identified in the reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent with medical knowledge and common sense. The contraindication in patients with significant liver disease and the caution advised for patients with[0m
[34mliver disease due to potential impairment of drug elimination logically support the conclusion that clonazepam may increase the risk of liver injury, especially in those with pre-existing liver [0m
[34mconditions. No specific flaws are identified in the reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent with medical knowledge and common sense. The contraindication in patients with significant liver disease and the caution advised for patients [0m
[31mwith liver disease due to potential impairment of drug elimination logically support the conclusion that clonazepam may increase the risk of liver injury, especially in those with pre-existing liver [0m
[31mconditions. No specific flaws are identified in the reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does CLONAZEPAM increase or decrease the risk of acute liver injury?"[0m[32m is that CLONAZEPAM may increase the risk of liver injury, especially in patients with [0m
[32mpre-existing liver disease. It is contraindicated in patients with significant liver disease, and caution is advised when administering it to patients with liver disease due to potential impairment of[0m
[32mdrug elimination. This conclusion is based on the information provided by FDAHandler, which indicates that CLONAZEPAM is contraindicated in patients with clinical or biochemical evidence of [0m
[32msignificant liver disease and that liver disease could impair clonazepam elimination.[0m
